kumorixilib

Kumorixilib (TQB3616) is an orally bioavailable, highly selective small molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). By specifically targeting these kinases, it prevents the phosphorylation of the retinoblastoma (Rb) protein, which is a critical step in the transition from the G1 to the S phase of the cell cycle. This inhibition leads to cell cycle arrest and suppresses the proliferation of tumor cells. Developed by Chia Tai Tianqing Pharmaceutical Group, kumorixilib is primarily being investigated for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. It is often studied in combination with endocrine therapies (such as letrozole or fulvestrant) or chemotherapy (such as capecitabine) to overcome resistance and improve clinical outcomes in both neoadjuvant and metastatic settings.

Other names

kumoriciclibKumorixilib